CVS Health (CVS)

CVS Health on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, federal contracts, earnings dates and insider trades. Listed on NYSE, classified by the SEC as retail-drug stores and proprietary stores.

Download CSV

16.5M

Short interest

settlement 2026-09-30

1.7

Days to cover

-1.5 days vs prior

22.9%

Short share of volume

2026-10-09

Fails to deliver

settlement 2026-09-09

Wed 28 Oct

Next earnings

estimated date

Insider flow, 90 days

0 buys, 0 sells

As of 2026-10-09.

Short interest

FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSON

As of 30 September 2026, short interest in CVS is 16,470,151 shares, down 1,644,500 shares over the last month. Over the last 48 readings it ranged from 13,670,187 shares (15 July 2025) to 23,623,517 shares (15 September 2025). At the reported average volume of 9.9M shares a day that is 1.7 days to cover.

Embed this chart.The embed keeps its attribution line.

<iframe src="https://xoomar.com/embed/stocks/cvs" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

Preview Dark previewAdd ?theme=dark to the src for a dark chart.

Settlement	Shares short	Change	Avg daily volume	Days to cover
2026-09-30	16,470,151	+2.1%	9,936,300	1.66
2026-09-15	16,123,980	-11.0%	5,132,435	3.14
2026-08-31	18,114,651	+7.7%	6,457,753	2.81
2026-08-14	16,823,735	-9.9%	9,344,565	1.80
2026-07-31	18,676,470	-4.3%	7,743,941	2.41
2026-07-15	19,524,883	-2.1%	7,190,543	2.72
2026-06-30	19,938,997	-14.0%	8,647,548	2.31
2026-06-15	23,194,154	+30.6%	8,557,677	2.71
2026-05-29	17,760,492	-9.0%	7,445,329	2.39
2026-05-15	19,520,276	+9.6%	9,894,225	1.97
2026-04-30	17,809,568	-3.0%	7,789,468	2.29
2026-04-15	18,350,833	-7.7%	7,276,376	2.52
2026-03-31	19,889,083	+11.7%	8,006,475	2.48
2026-03-13	17,812,471	+1.3%	7,472,378	2.38
2026-02-27	17,582,146	+6.4%	7,819,431	2.25
2026-02-13	16,528,176	-18.8%	9,397,283	1.76
2026-01-30	20,354,623	+8.5%	13,074,576	1.56
2026-01-15	18,762,000	-13.4%	7,566,253	2.48
2025-12-31	21,665,261	-5.5%	5,008,100	4.33
2025-12-15	22,923,080	+16.8%	8,975,125	2.55
2025-11-28	19,631,638	+1.8%	6,543,454	3.00
2025-11-14	19,288,799	+2.0%	6,615,706	2.92
2025-10-31	18,902,018	-3.2%	8,253,279	2.29
2025-10-15	19,523,681	+3.1%	7,789,299	2.51

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 9 October 2026, the short share of CVS volume is 22.9%, up 3.5 points over the last five sessions. Over the last 30 readings it ranged from 12.4% (5 October 2026) to 55.7% (18 September 2026). The latest reading is 10.7 points below the 30-session average of 33.6%, on 3.9M shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-10-09	886K	3.9M	22.9%	7,908
2026-10-08	494K	2.2M	22.4%	364
2026-10-07	795K	3.6M	22.1%	3,549
2026-10-06	886K	3.9M	22.6%	7,951
2026-10-05	592K	4.8M	12.4%	93
2026-10-02	711K	3.7M	19.4%	2,146
2026-10-01	1.0M	2.5M	39.9%	2,971
2026-09-30	1.1M	2.8M	38.0%	4,769
2026-09-29	879K	2.4M	36.4%	1,434
2026-09-28	1.4M	2.7M	50.8%	0
2026-09-25	1.5M	6.4M	23.1%	38,719
2026-09-24	707K	2.7M	26.5%	5,291
2026-09-23	581K	2.6M	22.2%	1,323
2026-09-22	1.2M	2.4M	48.9%	1,243
2026-09-21	1.0M	2.7M	38.9%	3,402
2026-09-18	2.5M	4.5M	55.7%	1,161
2026-09-17	905K	2.3M	40.0%	1,174
2026-09-16	704K	2.3M	30.5%	382
2026-09-15	550K	1.7M	32.3%	1,305
2026-09-14	418K	1.5M	28.3%	1,273
2026-09-11	577K	1.7M	34.8%	310
2026-09-10	367K	1.4M	26.2%	1,015
2026-09-09	688K	2.1M	33.4%	479
2026-09-08	421K	1.2M	33.8%	9,150
2026-09-04	737K	1.8M	41.7%	3,471
2026-09-03	819K	1.9M	42.4%	441
2026-09-02	1.1M	2.4M	47.0%	18,005
2026-09-01	1.6M	3.4M	48.1%	8,331
2026-08-31	667K	1.9M	35.7%	35,583
2026-08-28	525K	1.6M	32.8%	1,966

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 9 September 2026, the fails-to-deliver balance in CVS is 5 shares, down 11 shares over the last settlement date. Over the last 30 readings it ranged from 5 shares (9 September 2026) to 73,649 shares (22 June 2026). The latest reading sits at the bottom of that range.

Settlement	Shares failed	Price	Value
2026-09-09	5	$96.07	$480
2026-09-08	16	$96.74	$2K
2026-09-02	10	$97.60	$976
2026-09-01	2,607	$93.91	$245K
2026-08-28	632	$92.92	$59K
2026-08-27	2,918	$94.32	$275K
2026-08-26	2,808	$92.90	$261K
2026-08-06	71	$99.12	$7K
2026-07-22	12	$110.60	$1K
2026-07-21	12	$107.61	$1K
2026-07-20	17	$107.47	$2K
2026-07-17	12	$106.50	$1K
2026-07-16	12	$105.91	$1K
2026-07-15	12	$106.18	$1K
2026-07-14	461	$105.90	$49K
2026-07-13	12	$104.15	$1K
2026-07-10	812	$102.81	$83K
2026-07-09	30	$104.47	$3K
2026-07-08	12	$104.33	$1K
2026-07-07	12	$102.08	$1K
2026-07-06	165	$104.72	$17K
2026-07-02	59,440	$104.81	$6.2M
2026-07-01	12	$103.45	$1K
2026-06-30	12	$103.58	$1K
2026-06-29	12	$104.34	$1K
2026-06-26	12	$104.66	$1K
2026-06-25	12	$101.87	$1K
2026-06-24	12	$101.57	$1K
2026-06-22	73,649	$98.32	$7.2M
2026-06-12	2,400	$100.48	$241K

Insider trades

SEC Form 4, newest first, 50 of 100 shown. JSON

No open-market insider trades were reported for CVS in the last 90 days. The most recent filings are listed below. Latest filing: Clark James David (SVP, Cont & Chief Acct Officer) on 2026-06-26.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2026-06-26	Clark James David	SVP, Cont & Chief Acct Officer	Tax withholding	454	$90.98	$41K	28K
2026-05-31	Newman Brian	EVP, Chief Financial Officer	Tax withholding	2K	$90.98	$225K	3K
2026-05-31	Compton-Phillips Amy	EVP, Chief Medical Officer	Tax withholding	8K	$90.98	$693K	10K
2026-05-21	ROBBINS LARRY	Director	Sell	370K	$93.45	$34.6M	4.8M
2026-05-21	AGUIRRE FERNANDO	Director	Disposition	2K	$93.50	$146K	11K
2026-05-20	ROBBINS LARRY	Director	Sell	800	$96.28	$77K	5.2M
2026-05-20	ROBBINS LARRY	Director	Sell	67K	$95.67	$6.4M	5.2M
2026-05-20	ROBBINS LARRY	Director	Sell	153K	$94.81	$14.5M	5.3M
2026-05-20	ROBBINS LARRY	Director	Sell	798K	$93.48	$74.6M	5.4M
2026-05-20	AGUIRRE FERNANDO	Director	Disposition	30K	$93.78	$2.9M	12K
2026-05-19	ROBBINS LARRY	Director	Sell	151	$95.18	$14K	6.2M
2026-05-19	ROBBINS LARRY	Director	Sell	2.0M	$94.45	$187.3M	6.2M
2026-05-14	KIRBY J SCOTT	Director	Grant	1K	$97.15	$141K	14K
2026-05-14	Norwalk Leslie V	Director	Grant	1K	$97.15	$141K	7K
2026-05-14	SANSONE GUY P	Director	Grant	1K	$97.15	$141K	15K
2026-05-14	Balser Jeffrey R.	Director	Grant	2K	$97.15	$200K	16K
2026-05-14	BROWN C DAVID II	Director	Grant	2K	$97.15	$150K	129K
2026-05-14	AGUIRRE FERNANDO	Director	Grant	2K	$97.15	$152K	43K
2026-05-08	Mandadi Tilak	EVP, Chief Exp & Tech Officer	Sell	70K	$89.58	$6.2M	10K
2026-04-01	Shah Prem S	EVP and Group President	Tax withholding	1K	$72.49	$108K	64K
2026-04-01	Nelson Steven H	EVP and President, Aetna	Tax withholding	2K	$72.49	$176K	3K
2026-04-01	Mandadi Tilak	EVP, Chief Exp & Tech Officer	Tax withholding	4K	$72.49	$263K	80K
2026-04-01	Khichi Samrat S.	EVP, CPO and General Counsel	Tax withholding	4K	$72.49	$257K	33K
2026-04-01	Joyner J. David	President, CEO and Chair	Tax withholding	8K	$72.49	$582K	70K
2026-04-01	Clark James David	SVP, Cont & Chief Acct Officer	Tax withholding	3K	$72.49	$236K	15K
2026-04-01	CAPOZZI HEIDI B	EVP and Chief People Officer	Tax withholding	1K	$72.49	$97K	13K
2026-03-31	Shah Prem S	EVP and Group President	Grant	25K	$71.82	$1.8M	63K
2026-03-31	Newman Brian	EVP, Chief Financial Officer	Grant	19K	$71.82	$1.4M	41K
2026-03-31	Nelson Steven H	EVP and President, Aetna	Grant	22K	$71.82	$1.6M	44K
2026-03-31	Mandadi Tilak	EVP, Chief Exp & Tech Officer	Grant	22K	$71.82	$1.6M	89K
2026-03-31	Khichi Samrat S.	EVP, CPO and General Counsel	Grant	13K	$71.82	$900K	38K
2026-03-31	Joyner J. David	President, CEO and Chair	Grant	86K	$71.82	$6.2M	161K
2026-03-31	Compton-Phillips Amy	EVP, Chief Medical Officer	Grant	6K	$71.82	$400K	59K
2026-03-31	Clark James David	SVP, Cont & Chief Acct Officer	Grant	11K	$71.82	$800K	36K
2026-03-31	CAPOZZI HEIDI B	EVP and Chief People Officer	Grant	10K	$71.82	$720K	84K
2026-03-19	Gallina John E	Director	Grant	582	$71.86	$42K	582
2026-02-28	Khichi Samrat S.	EVP, CPO and General Counsel	Tax withholding	8K	$79.60	$628K	30K
2026-02-28	Joyner J. David	President and CEO	Tax withholding	2K	$79.90	$155K	50K
2026-01-01	Shah Prem S	EVP and Group President	Tax withholding	247	$80.13	$20K	62K
2025-12-01	Clark James David	SVP, Cont & Chief Acct Officer	Tax withholding	220	$79.10	$17K	24K
2025-11-30	Mandadi Tilak	EVP, Chief Exp & Tech Officer	Tax withholding	7K	$80.36	$528K	74K
2025-11-30	FARAH ROGER N	Director	Tax withholding	10K	$80.36	$783K	19K
2025-11-30	CAPOZZI HEIDI B	EVP and Chief People Officer	Tax withholding	9K	$80.36	$761K	11K
2025-11-20	Shulman Douglas H.	Director	Grant	2K	$76.04	$126K	6K
2025-11-20	SANSONE GUY P	Director	Grant	2K	$76.04	$126K	14K
2025-11-20	Norwalk Leslie V	Director	Grant	2K	$76.04	$126K	6K
2025-11-20	KIRBY J SCOTT	Director	Grant	2K	$76.04	$126K	13K
2025-11-20	Finucane Anne A.	Director	Grant	591	$76.04	$45K	591
2025-11-20	Balser Jeffrey R.	Director	Grant	2K	$76.04	$135K	14K
2025-11-20	BROWN C DAVID II	Director	Grant	2K	$76.04	$135K	128K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Planned sales (Form 144)

Newest first. JSON

3 Form 144 notices on file for CVS worth $6.7M at the prices reported; 0 in the last 90 days worth $0. Latest: AGUIRRE FERNANDO filed on 2026-05-22 to sell 2,263 shares ($214K) from 2026-05-20.

Filed	Seller	Shares	Market value	Of outstanding	Sale from	Broker
2026-05-22	AGUIRRE FERNANDODirector	2K	$214K	0.000%	2026-05-20	TD Securities (USA) LLC
2026-05-21	FARAH ROGER NDirector	3K	$264K	0.000%	2026-05-21	Charles Schwab Corp.
2026-05-08	TILAK MANDADIOfficer	70K	$6.2M	0.005%	2026-05-08	Morgan Stanley Smith Barney LLC Executive Financial Services

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

1 holder reports 5% or more of CVS in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.5% of the class (95,598,528 shares), filed 2026-04-29 for an event on 2026-03-31.

Filed	Form	Holder	Shares	Of class	Event
2026-08-13	13G/Ano. 1	Dodge & Coxinvestment adviser	50.0M	3.9%	2026-06-30
2026-04-29	13G	Vanguard Capital Managementinvestment adviser	95.6M	7.5%	2026-03-31
2026-03-26	13G/Ano. 10	The Vanguard Groupinvestment adviser	0	0.0%	2026-03-13

13F holders

Tracked managers holding CVS at their latest 13F. JSON

9 of the 30 tracked managers held CVS at their latest 13F, $1.80B in total at quarter-end prices. Citadel Advisors is the largest at $497.9M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 3 cut.

Fund	Quarter	Shares	Value	Of portfolio	Change in shares
Citadel Advisors	2026-06-30	4.8M	$497.9M	0.06%	-616K
Viking Global Investors	2026-06-30	3.7M	$379.0M	1.08%	new
AQR Capital Management	2026-06-30	2.4M	$248.9M	0.09%	+24K
Millennium Management	2026-06-30	2.2M	$224.0M	0.08%	+2.0M
Point72 Asset Management	2026-06-30	2.0M	$202.9M	0.22%	new
D. E. Shaw & Co.	2026-06-30	1.4M	$143.0M	0.07%	-235K
Renaissance Technologies	2026-06-30	441K	$45.6M	0.06%	+178K
Bridgewater Associates	2026-06-30	441K	$45.6M	0.19%	-177K
Fisher Asset Management	2026-06-30	92K	$9.5M	0.00%	+4K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In Q2 FY 2026 (quarter ended 2026-06-30) CVS Health reported revenue of $106.10B, up 7.3% from the same quarter a year earlier, and net income of $2.98B (2.31 diluted EPS). In FY 2025 it generated $10.64B of operating cash flow and spent $3.40B on dividends.

Cash: $11.33B
Equity: $79.70B
Total assets: $253.77B
Shares outstanding: 1,278,970,369

Quarterly, last 8 quarters

Quarter	Period end	Revenue	Net income	Margin	Diluted EPS
Q2 FY 2026	2026-06-30	$106.10B	$2.98B	2.8%	2.31
Q1 FY 2026	2026-03-31	$100.43B	$2.94B	2.9%	2.30
Q4 FY 2025derived	2025-12-31	$105.69B	$2.94B	2.8%	n/a
Q3 FY 2025	2025-09-30	$102.87B	-$3.98B	-3.9%	-3.13
Q2 FY 2025	2025-06-30	$98.92B	$1.02B	1.0%	0.80
Q1 FY 2025	2025-03-31	$94.59B	$1.78B	1.9%	1.41
Q4 FY 2024derived	2024-12-31	$97.71B	$1.64B	1.7%	n/a
Q3 FY 2024	2024-09-30	$95.43B	$87.0M	0.1%	0.07

Fiscal years, with buybacks and dividends

Fiscal year	Ends	Revenue	Net income	Operating cash flow	Capex	Buybacks	Dividends
FY 2025	2025-12-31	$402.07B	$1.77B	$10.64B	$2.83B	$0	$3.40B
FY 2024	2024-12-31	$372.81B	$4.61B	$9.11B	$2.78B	$3.02B	$3.37B
FY 2023	2023-12-31	$357.78B	$8.34B	$13.43B	$3.03B	$2.01B	$3.13B
FY 2022	2022-12-31	$322.47B	$4.31B	$16.18B	$2.73B	$3.50B	$2.91B
FY 2021	2021-12-31	$292.11B	$8.00B	$18.27B	$2.52B	$0	$2.63B

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-29 from the cover page.

Federal contracts

The largest contract actions for CVS Health and its subsidiaries. JSON

1 contract action on file for CVS: $7.0M obligated in the last 90 days and $7.0M in the last 12 months across 1 awarding agency. The largest was $7.0M from the Department of Health and Human Services on 2026-09-25 (best 3 task order; health care data sources for surveillance of biologics. eo 14398). This covers the largest contract actions, not every award, and agencies report late.

Action date	Agency	Amount	Type	Description
2026-09-25	Department of Health and Human ServicesFood and Drug Administration	$7.0M	new awarddelivery order	BEST 3 TASK ORDER; HEALTH CARE DATA SOURCES FOR SURVEILLANCE OF BIOLOGICS. EO 14398USAspending

What this page is

CVS Health in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows CVS Health (CVS), SEC CIK 64803, listed on NYSE, classified by the SEC as retail-drug stores and proprietary stores. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest: FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
Fails to deliver: SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-09.JSON and CSV
Planned sales: SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-05-22.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
13F holders: SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Financials: SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
Federal contracts: USAspending.govSource: USAspending.gov.The largest contract actions each day, as agencies report them (up to 90 days late). Latest 2026-09-25.JSON and CSV
Earnings dates: SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-26.JSON and CSV
Company record: EDGAR filing index for CIK 64803Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as retail-drug stores and proprietary stores

YI111

Datasets

Frequently Asked Questions

How much of CVS is sold short?

16,470,151 shares were held short at the 2026-09-30 settlement, 1.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.

What is CVS's daily short volume?

On 2026-10-09, 886,363 of the 3,868,539 CVS shares reported to FINRA were sold short, 22.9% of the day's reported volume. Short volume is a flow for one day, not a position.

Does CVS have fails to deliver?

The SEC's latest file shows 5 CVS shares failed to deliver at settlement 2026-09-09. Fails are reported per settlement date and published twice a month with a lag.

Are CVS insiders buying or selling?

No open-market insider trades were reported for CVS in the last 90 days. The most recent filings are listed below. Latest filing: Clark James David (SVP, Cont & Chief Acct Officer) on 2026-06-26.

Have CVS insiders filed to sell?

3 Form 144 notices on file for CVS worth $6.7M at the prices reported; 0 in the last 90 days worth $0. Latest: AGUIRRE FERNANDO filed on 2026-05-22 to sell 2,263 shares ($214K) from 2026-05-20.

Who owns 5% or more of CVS?

What did CVS report last quarter?

Which tracked 13F managers own CVS?

9 of the 30 tracked 13F managers held CVS shares at their latest filing, $1.80B in all. The largest: Ken Griffin's Citadel Advisors (4.8M shares, $497.9M), Andreas Halvorsen's Viking Global Investors (3.7M shares, $379.0M), Cliff Asness's AQR Capital Management (2.4M shares, $248.9M), Izzy Englander's Millennium Management (2.2M shares, $224.0M), Steve Cohen's Point72 Asset Management (2.0M shares, $202.9M), D. E. Shaw & Co. (1.4M shares, $143.0M). The table above lists all 9.

How much federal contract money did CVS receive?

$7.0M was obligated to CVS Health and its subsidiaries in the last 90 days and $7.0M in the last 12 months, counting the largest contract actions on USAspending, not every award. Obligations are not revenue; they are spent over each contract's life.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.

CVS Health (CVS)

Short interest

Daily short volume

Fails to deliver

Insider trades

Planned sales (Form 144)

Large holders (13D and 13G)

13F holders

Financials

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Federal contracts

CVS Health in the regulatory record

Source and updates

How to read it

Other companies the SEC classifies as retail-drug stores and proprietary stores

Other company pages

Datasets

Frequently Asked Questions